Abstract
TPS148 Background: For patients with 1-3 brain metastases, standard therapy after stereotactic radiosurgery (SRS) is whole brain radiotherapy (WBRT). SRS without WBRT leads to a significantly higher rate of relapse in the brain and local site (Aoyama, JAMA, 2006). Due to concerns about neurologic sequelae of WBRT, however, a substantial number of patients and physicians opt to delay WBRT until the time of CNS progression. This trial offers chemotherapy as an alternative treatment to WBRT for this patient subgroup. Sunitinib targets VEGFR and therefore vasculature. Because this target lies on the abluminal side of the blood brain barrier (BBB), sunitinib should not need to cross the BBB. Sunitinib might be effective in preventing growth of microscopic brain metastases. This trial uses sunitinib after SRS with the goal of preventing recurrent disease in the brain and at the site of SRS and preserving neurocognitive function (NCF). The hypothesis is that sunitinib will provide an effective alternative to WBR...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
